HIMS vs. NTRA, FMS, OPCH, GH, RDNT, SHC, BTSG, SGRY, WGS, and PRVA
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care (FMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), BrightSpring Health Services (BTSG), Surgery Partners (SGRY), GeneDx (WGS), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs.
Natera (NASDAQ:NTRA) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
Natera has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
Natera received 447 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 68.92% of users gave Natera an outperform vote while only 37.07% of users gave Hims & Hers Health an outperform vote.
In the previous week, Hims & Hers Health had 7 more articles in the media than Natera. MarketBeat recorded 25 mentions for Hims & Hers Health and 18 mentions for Natera. Natera's average media sentiment score of 1.39 beat Hims & Hers Health's score of 1.08 indicating that Natera is being referred to more favorably in the media.
Natera currently has a consensus price target of $178.12, suggesting a potential upside of 20.11%. Hims & Hers Health has a consensus price target of $37.31, suggesting a potential upside of 16.75%. Given Natera's stronger consensus rating and higher possible upside, research analysts plainly believe Natera is more favorable than Hims & Hers Health.
99.9% of Natera shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 7.6% of Natera shares are owned by company insiders. Comparatively, 17.7% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Hims & Hers Health has a net margin of 8.19% compared to Natera's net margin of -14.01%. Hims & Hers Health's return on equity of 10.97% beat Natera's return on equity.
Hims & Hers Health has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Summary
Natera beats Hims & Hers Health on 10 of the 18 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy HIMS Stock Free HIMS Stock Alerts